Physician profile
Peter E Graham
NPI 1841385226
$268.15
in general payments reported to CMS, 2019-2025
12 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2020: $28.47 · 2021: $51.63 · 2022: $188.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Array Biopharma INC | $34.24 | 2021 | |
| Astrazeneca Pharmaceuticals Lp | $32.54 | 2021-2022 | |
| Genzyme Corporation | $30.14 | 2022 | |
| Rigel Pharmaceuticals, INC. | $30.07 | 2020-2022 | |
| Amag Pharmaceuticals, INC. | $28.42 | 2022 | |
| Incyte Corporation | $20.48 | 2022 | |
| Daiichi Sankyo INC. | $19.30 | 2022 | |
| Astellas Pharma US INC | $16.12 | 2022 | |
| Bayer Healthcare Pharmaceuticals INC. | $15.66 | 2022 | |
| Amgen INC. | $14.64 | 2020 | |
| Pharmacosmos Therapeutics INC. | $13.64 | 2022 | |
| Tersera Therapeutics LLC | $12.90 | 2022 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Peter Graham listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.